Episode 169: Pancreatic Cancer Series, Pt. 4 – Metastatic Disease

Episode 169: Pancreatic Cancer Series, Pt. 4 – Metastatic Disease

This week, we continue our Pancreatic Cancer series with the setting where most of our patients live: metastatic disease. Using our case of a patient with newly diagnosed metastatic pancreatic cancer, we trace how first-line chemotherapy evolved from single-agent gemcitabine to FOLFIRINOX, gemcitabine/nab-paclitaxel, and NALIRIFOX, then work through how to pick a regimen for the patient in front of you, why germline and somatic testing belong at the first visit, what the POLO trial does and doesn't tell us about maintenance olaparib, and the story of the year: daraxonrasib, the RAS(ON) inhibitor that finally drugged the "undruggable" target in RASolute 302. We finish with second-line sequencing.

As always, if you haven't heard the earlier episodes in this series, including our introduction, approach to resectable disease, and approach to borderline and locally advanced disease, be sure to check those out first.

And listeners - stay tuned! We will follow up these conversations with our interviews with our surgery and radiation colleagues in upcoming episodes!

Sign up to read this post
Join Now
Previous
Previous

Episode 170: Career Development Series- How to Navigate the ASH Annual Meeting

Next
Next

Episode 168: Pancreatic Cancer Series, Pt. 3 – Borderline Resectable and Locally Advanced Disease